Premium
The Influence of the Menstrual Cycle on Triazolam and Indocyanine Green Pharmacokinetics
Author(s) -
Kamimori Gary H.,
Sirisuth Nattee,
Greenblatt David J.,
Eddington Natalie D.
Publication year - 2000
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700022009495
Subject(s) - triazolam , pharmacokinetics , luteal phase , indocyanine green , menstrual cycle , follicular phase , chemistry , bolus (digestion) , pharmacology , endocrinology , medicine , benzodiazepine , surgery , biochemistry , hormone , receptor
The aim of this study was to investigate the effects of the menstrual cycle phase on the pharmacokinetics of two high‐clearance agents, triazolam and indocyanine green (ICG). Eleven nonsmoking, healthy, eumenorrheic women were enrolled in this study. Triazolam (0.25 mg) was administered orally, and indocyanine green was administered as an i.v. bolus (0.5 mg/kg) during the follicular, ovulatory, and luteal phases of a single menstrual cycle. Blood samples were collected over 10 hours for triazolam and over 30 minutes for ICG. Triazolam and indocyanine green concentrations were quantitated by electron capture gas chromatography and spectrophotometry, respectively. Noncompartmental analysis was used to determine relevant pharmacokinetics parameters, which were statistically assessed using two‐way ANOVA (p < 0.05). No statistical differences for triazolam were observed. Vd/F was lower in the luteal phase (107 L) as compared to the follicular (138 L) and ovulatory (133 L) phases. Clearance of triazolam was comparable in the follicular (583 ml/min), ovulatory (565 ml/min), and luteal (538 ml/min) phases. ICG also revealed no significant differences across the phases. These results suggest that the phases of the menstrual cycle do not influence triazolam or ICG pharmacokinetics.